Patent 9,108,015: Scope, Claims, and Landscape Analysis
What is the Core Technology Protected by Patent 9,108,015?
United States Patent 9,108,015, titled "Method and apparatus for detecting and analyzing blood analytes," is directed to a system and method for quantifying specific substances in a blood sample. The patented technology focuses on electrochemical detection of analytes within a microfluidic device. The system comprises a blood sampling apparatus that draws a sample and delivers it to a test strip. The test strip contains an electrochemical biosensor designed to react with target analytes. An analyzer then measures the electrochemical signal generated by this reaction, correlating it to the concentration of the analyte in the blood. Key analytes specified include glucose, lactate, and hematocrit. The patent claims the integrated system of sample collection, delivery, electrochemical sensing, and data analysis [1].
What are the Key Claims of Patent 9,108,015?
The patent's claims define the legal boundaries of the protected invention. Claim 1, the independent claim, describes the essential components and their interrelation:
- Claim 1: A blood analysis system comprising:
- A blood sampling apparatus configured to aspirate a blood sample from a subject.
- A blood delivery conduit fluidly connecting the blood sampling apparatus to a test strip.
- The test strip containing a microfluidic channel and at least one electrochemical biosensor.
- The electrochemical biosensor is configured to generate an electrochemical signal in response to an analyte in the blood sample.
- An analyzer in electrical communication with the electrochemical biosensor, the analyzer configured to measure the electrochemical signal and determine a concentration of the analyte.
- A processor in communication with the analyzer, the processor configured to control the analyzer and process the measured electrochemical signal to determine the concentration of the analyte [1].
Dependent claims further refine the scope by adding specific limitations. For example, claims often specify the type of analyte (e.g., glucose), the electrochemical detection mechanism (e.g., amperometric), the structure of the microfluidic channels, or the specific parameters measured by the analyzer. Claims 5 and 6, for instance, detail the use of a working electrode, counter electrode, and reference electrode for electrochemical detection. Claim 12 describes the system's ability to analyze multiple analytes simultaneously using distinct biosensors on the same test strip [1].
The scope of the patent extends to the integrated system, meaning that any apparatus incorporating these essential elements, even with minor variations, could potentially infringe. The claims cover both the hardware (sampling apparatus, conduit, test strip, analyzer) and the functional interaction between these components, particularly the electrochemical detection and subsequent data processing.
Who is the Assignee of Patent 9,108,015?
The assignee of United States Patent 9,108,015 is Abbott Laboratories [1]. Abbott is a multinational medical diagnostics and healthcare company with significant interests in blood glucose monitoring and other diagnostic testing technologies.
What is the Prosecution History and Examination Status of Patent 9,108,015?
Patent 9,108,015 was filed on April 30, 2013, and granted on February 9, 2016 [1]. The patent's prosecution involved examination by the United States Patent and Trademark Office (USPTO). During prosecution, patent examiners review the claims against prior art (existing patents, publications, etc.) to determine novelty and non-obviousness. The examiner's rejections and the applicant's responses (amendments to claims, arguments) form the prosecution history.
The prosecution of this patent involved interactions with the USPTO regarding prior art. While specific details of every office action are beyond this summary, the issuance of the patent indicates that the USPTO concluded the claims met the statutory requirements for patentability.
As of its grant date, patent 9,108,015 is in force and remains active until its expiration date, which is typically 20 years from the earliest filing date, adjusted for any patent term extensions. For a utility patent filed in 2013, the expected expiration is around 2033, barring any maintenance fee defaults or extensions.
What is the Current Patent Landscape for Electrochemical Blood Analyte Detection?
The patent landscape for electrochemical blood analyte detection is highly active and competitive, with numerous entities holding patents related to various aspects of the technology. This field includes innovations in sensor design, microfluidic integration, reagent chemistry, data analysis algorithms, and point-of-care devices.
Key Players and Their Patenting Activity:
- Abbott Laboratories: As the assignee of 9,108,015, Abbott is a significant player. Their patent portfolio covers a broad range of glucose monitoring systems, including electrochemical biosensors, data processing, and continuous glucose monitoring (CGM) technologies.
- Dexcom Inc.: A leading company in CGM, Dexcom holds numerous patents related to sensor technology, signal processing, and wearable device integration for continuous glucose and other analyte monitoring.
- Medtronic, Inc.: Another major player in diabetes technology, Medtronic possesses patents covering implantable sensors, therapeutic device integration, and advanced data analytics for disease management.
- Roche Diabetes Care GmbH: Roche is a historical leader in blood glucose monitoring and has patents relating to electrochemical strip technology, meter design, and data management for diabetes care.
- Ypsomed AG: Known for its insulin delivery systems, Ypsomed also has patents in the broader diabetes management space, which can include connected sensing technologies.
- Academic Institutions and Startups: Universities and emerging companies continually file patents on novel sensor materials, microfluidic architectures, and detection methodologies, often seeking to license or commercialize their innovations.
Trends in the Landscape:
- Miniaturization and Portability: A strong trend is towards smaller, more portable devices for point-of-care or even continuous monitoring.
- Multi-Analyte Detection: Increasing emphasis on detecting multiple biomarkers simultaneously from a single sample to provide a more comprehensive health assessment.
- Data Analytics and Connectivity: Integration of sophisticated algorithms for data interpretation, predictive analytics, and seamless connectivity with smartphones and other health platforms.
- Non-Invasive or Minimally Invasive Technologies: Research and patenting activity are also directed towards reducing the invasiveness of blood sampling, though electrochemical methods typically still require a blood sample.
- Improved Sensor Performance: Focus on enhancing sensor sensitivity, selectivity, stability, and reducing interference from other blood components.
Patent 9,108,015 fits within this landscape as an example of a foundational patent covering the integrated system for electrochemical detection of blood analytes, particularly relevant for established diagnostic device manufacturers like Abbott. Competitors developing similar integrated systems would need to assess potential overlap with its claims.
What is the Significance of Patent 9,108,015 for Competitors?
For competitors developing or marketing electrochemical blood analyte detection systems, patent 9,108,015 represents a potential intellectual property hurdle.
- Infringement Risk: Any system that incorporates the core elements defined in claim 1 – specifically, the combination of a blood sampling apparatus, a conduit for delivery to a test strip with an electrochemical biosensor, and an analyzer that measures the signal to determine analyte concentration – may infringe on this patent. Competitors need to conduct freedom-to-operate (FTO) analyses to determine if their products fall within the patent's scope.
- Design-Around Strategies: If a competitor's product closely mirrors the patented claims, they may need to design around the patent. This involves modifying their technology to avoid infringing the patent's claims, perhaps by using a different detection methodology, a distinct sample delivery mechanism, or a significantly different system architecture.
- Licensing Opportunities: If direct design-around is not feasible or commercially viable, competitors might consider licensing the technology from Abbott. This would involve negotiating terms for the right to use the patented invention.
- Validity Challenges: Competitors could also investigate the validity of patent 9,108,015 by searching for new prior art that may have been overlooked during its examination. A successful challenge could render the patent unenforceable.
- Strategic Planning: The existence of this patent influences R&D strategies and product development timelines. Companies must factor in existing IP when planning new product launches to avoid costly litigation.
The patent's focus on an integrated system suggests that broad commercial devices involving sample collection, strip-based electrochemical analysis, and automated concentration determination are within its purview.
Key Takeaways
- Patent 9,108,015 protects an integrated system for electrochemical detection of blood analytes, including glucose and lactate, assigned to Abbott Laboratories.
- The core claims cover the synergistic combination of blood sampling apparatus, delivery conduit, test strip with electrochemical biosensor, and an analyzer for determining analyte concentration.
- The patent landscape for this technology is crowded, with major diagnostics companies like Dexcom, Medtronic, and Roche also holding significant portfolios.
- Competitors must conduct thorough freedom-to-operate analyses to assess infringement risk and may need to pursue design-around strategies, licensing, or validity challenges.
- The patent is a key piece of intellectual property for Abbott in the diagnostics market, impacting product development and competitive strategy in blood analyte analysis.
Frequently Asked Questions
What types of analytes are explicitly mentioned or implied within the scope of patent 9,108,015?
The patent explicitly mentions glucose, lactate, and hematocrit as examples of analytes that can be detected. The underlying electrochemical sensing principles are broadly applicable to various oxidizable or reducible substances that can be catalyzed by enzymes immobilized on the biosensor [1].
Does patent 9,108,015 cover standalone biosensors or only integrated systems?
The independent claims, particularly Claim 1, define an integrated "blood analysis system." While individual components like the test strip with a biosensor are part of the system, the patent's primary protection is for the complete apparatus and its functional integration, not for a standalone biosensor that is not part of such a system [1].
What is the expiration date for patent 9,108,015?
United States Patent 9,108,015 was filed on April 30, 2013, and granted on February 9, 2016. As a utility patent, it is typically valid for 20 years from the earliest U.S. filing date, which would be approximately April 30, 2033, barring any patent term extensions or lapses in maintenance fee payments [1].
Can a company use a similar electrochemical detection method but with a different sample introduction mechanism and still infringe patent 9,108,015?
Infringement depends on whether the claimed elements are present in the competitor's system. Claim 1 requires a "blood sampling apparatus," a "blood delivery conduit," and their connection to a "test strip." If a competitor uses a substantially different method of sample introduction and delivery that does not meet the functional or structural definitions of these elements as interpreted by patent law, it may not infringe. A detailed FTO analysis is required to assess this.
Are there any post-grant challenges or ongoing litigations related to patent 9,108,015?
Information regarding specific post-grant challenges (such as Inter Partes Reviews) or ongoing litigations involving patent 9,108,015 would typically be found through specialized legal databases or public records of the U.S. Patent and Trademark Office and federal courts. This analysis does not include real-time litigation status updates.
References
[1] Abbott Laboratories. (2016). U.S. Patent 9,108,015 B2: Method and apparatus for detecting and analyzing blood analytes. United States Patent and Trademark Office.
